Details for New Drug Application (NDA): 050756
✉ Email this page to a colleague
NDA 050756 describes BENZACLIN, which is a drug marketed by Bausch and is included in one NDA. Additional details are available on the BENZACLIN profile page.
The generic ingredient in BENZACLIN is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.
The generic ingredient in BENZACLIN is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.
Summary for 050756
| Tradename: | BENZACLIN |
| Applicant: | Bausch |
| Ingredient: | benzoyl peroxide; clindamycin phosphate |
| Patents: | 0 |
Pharmacology for NDA: 050756
| Physiological Effect | Decreased Sebaceous Gland Activity Neuromuscular Blockade |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GEL;TOPICAL | Strength | 5%;EQ 1% BASE | ||||
| Approval Date: | Dec 21, 2000 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GEL;TOPICAL | Strength | 5%;EQ 1% BASE | ||||
| Approval Date: | Apr 20, 2007 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
